Improve the health of the people of Wisconsin by supporting and strengthening physicians' ability to practice high-quality patient care in a changing environment.

State boards indicate flexibility in manner of ePDMP compliance

Two State of Wisconsin regulatory boards reiterated support for widespread physician utilization of the enhanced Prescription Drug Monitoring Program (ePDMP) in separate meetings in Madison this week.

Members of both the Controlled Substances Board (CSB) and the Medical Examining Board (MEB) stated that they have heard physicians’ worries over compliance with the new law requiring physicians and other prescribers to review patient records from the ePDMP before issuing a prescription order for most controlled substances. On Monday the CSB—responsible for any rulemaking for the ePDMP—passed a motion indicating its focus on promoting the ePDMP and educating prescribers about its usefulness:

“The Board…recognizes that the priority will be to continue promoting, educating and training practitioners about the benefits of the PDMP and the requirements…regarding a practitioner’s review of ePDMP data. Further, the Board recognizes it has discretion in its authority for non-compliance of its rules that implement 2015 Act 266 to refer non-compliant practitioners to the regulatory authority that regulates the profession of the non-compliant practitioner.”

On Wednesday the MEB—which investigates complaints against Wisconsin-licensed physicians—discussed the legislative intent behind the law and how the ePDMP is intended to be a tool, not an administrative burden. Physician members of the MEB discussed how the new law allows delegates to access ePDMP patient data and work collaboratively with prescribers to identify information that warrants closer scrutiny.

The Society has been active in communicating physicians’ praise for and concerns over the ePDMP with both boards, the Department of Safety and Professional Services, the Department of Justice and state legislative leaders. All entities agree with the Society’s goal to make ePDMP implementation a collaborative effort aimed at providing important information to physicians and other prescribers to curb opioid abuse and increase patient safety.

Society members are encouraged to watch for a special Medigram Alert next week that will provide more in-depth information about the new requirement. The FAQ-style resource will summarize the law’s requirements, explain the exceptions and discuss potential workflow issues and strategies to make regular use of the ePDMP a valuable tool instead of a burden.

Contact Mark Grapentine, JD, or John Rather, JD, for more information.

Back to March 16, 2017 Medigram